

# Mariagrazia Rumi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5208557/publications.pdf>

Version: 2024-02-01

125  
papers

5,502  
citations

109137

35  
h-index

85405

71  
g-index

126  
all docs

126  
docs citations

126  
times ranked

5809  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study. <i>Hepatology Communications</i> , 2022, 6, 867-877.	2.0	6
2	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	3.6	12
3	Left ventricular strain predicts subclinical atherosclerosis in nonadvanced nonalcoholic fatty liver disease patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, Publish Ahead of Print, .	0.8	1
4	Hepatitis C virus screening in the 1969-1989 birth cohort: Is not enough!. <i>Liver International</i> , 2022, 42, 1915-1915.	1.9	4
5	Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood?. <i>Lancet Haematology</i> , 2021, 8, e8-e10.	2.2	0
6	High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , 2020, 73, 1063-1071.	1.8	279
7	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 593-602.	1.8	38
8	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	1.9	8
9	Minimal increases of serum alpha-fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. <i>Liver International</i> , 2019, 39, 1964-1974.	1.9	11
10	Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, 1135-1140.	0.4	18
11	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2019, 70, 379-387.	1.8	109
12	Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. <i>Digestive and Liver Disease</i> , 2019, 51, 419-424.	0.4	9
13	Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma. <i>Digestive and Liver Disease</i> , 2019, 51, 719-723.	0.4	11
14	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. <i>Liver International</i> , 2018, 38, 1459-1467.	1.9	22
15	Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 431-439.	1.9	7
16	Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 226-227.	1.9	2
17	Management of HCV-Related Liver Disease in Hemophilia and Thalassemia. <i>Seminars in Liver Disease</i> , 2018, 38, 112-120.	1.8	11
18	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0172159.	1.1	42

#	ARTICLE	IF	CITATIONS
19	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE, 2017, 12, e0185728.	1.1	37
20	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS ONE, 2016, 11, e0155967.	1.1	23
21	HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin. Journal of Hepatology, 2016, 65, 1058-1059.	1.8	2
22	Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity. PLoS ONE, 2015, 10, e0138546.	1.1	14
23	Telaprevir in a Patient with Chronic Hepatitis C and Cryoglobulinemic Glomerulonephritis. Antiviral Therapy, 2014, 19, 527-531.	0.6	18
24	Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir. PLoS ONE, 2014, 9, e95881.	1.1	13
25	Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. Thrombosis and Haemostasis, 2014, 111, 1067-1076.	1.8	6
26	The Association of IL28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent. International Journal of Molecular Sciences, 2014, 15, 7213-7224.	1.8	19
27	HCV E1E2 MF vaccine in chronic hepatitis C patients treated with PEG-IFN1±2a and R/ibavirin: a randomized controlled trial. Journal of Viral Hepatitis, 2014, 21, 458-465.	1.0	19
28	Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. Journal of Viral Hepatitis, 2014, 21, 416-423.	1.0	11
29	Interleukin 28B Genotype and Insulin Resistance in Chronic Hepatitis C Patients. Antiviral Therapy, 2014, 19, 747-753.	0.6	6
30	The diagnostic accuracy of Fibroscan® for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. Journal of Hepatology, 2013, 59, 251-256.	1.8	131
31	Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. Journal of Hepatology, 2013, 59, 38-44.	1.8	52
32	Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients. BioMed Research International, 2013, 2013, 1-6.	0.9	3
33	Predictors of Psychopathological Outcome During Peg-Interferon and Ribavirin Therapy in Patients with Chronic HCV-Correlated Hepatitis. Journal of Interferon and Cytokine Research, 2013, 33, 9-14.	0.5	2
34	Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. Journal of Viral Hepatitis, 2013, 20, 858-866.	1.0	32
35	934 DIFFERENCES IN HCV GENOTYPE 1 RVR RATES AMONG CLINICAL TRIALS IN EUROPE DEPEND ON HCV RNA ASSAY SENSITIVITY. Journal of Hepatology, 2012, 56, S364.	1.8	2
36	Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology, 2012, 56, 1681-1687.	3.6	83

#	ARTICLE	IF	CITATIONS
37	Hyporesponsiveness to PegIFN±2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. <i>Journal of Hepatology</i> , 2012, 56, 341-347.	1.8	21
38	Antiviral Therapy for HCV-Associated Cryoglobulinemic Glomerulonephritis: Case Report and Review of the Literature. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 687-693.	0.9	7
39	A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. <i>Hepatology</i> , 2012, 56, 532-543.	3.6	354
40	Comparative trials of peginterferon ±2a and peginterferon ±2b for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 37-41.	1.0	7
41	Implications of <i>PNPLA3</i> polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1434-1442.	1.9	35
42	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. <i>Hepatology</i> , 2012, 55, 336-342.	3.6	81
43	Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. <i>Journal of Hepatology</i> , 2011, 54, 621-628.	1.8	110
44	The Course of Esophageal Varices in Patients with Hepatitis C Cirrhosis Responding to Interferon/Ribavirin Therapy. <i>Antiviral Therapy</i> , 2011, 16, 677-684.	0.6	48
45	Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. <i>Hepatology</i> , 2011, 53, 791-799.	3.6	227
46	Genetic variation in the <i>interleukin-28B</i> gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. <i>Hepatology</i> , 2011, 54, 1127-1134.	3.6	115
47	Ribavirin Impairs Salivary Gland Function in Hepatitis C Patients During Combination Treatment With Pegylated Interferon Alfa-2a. <i>Hepatitis Monthly</i> , 2011, 11, 918-924.	0.1	10
48	Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. <i>Hepatitis Monthly</i> , 2011, 11, 918-924.	0.1	7
49	Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy. <i>Hepatology</i> , 2010, 52, 1170-1171.	3.6	9
50	The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. <i>Gut</i> , 2010, 59, 638-644.	6.1	358
51	Randomized Study of Peginterferon±2a Plus Ribavirin vs Peginterferon±2b Plus Ribavirin in Chronic Hepatitis C. <i>Gastroenterology</i> , 2010, 138, 108-115.	0.6	190
52	Pegylated interferons ±2a and ±2b in the treatment of chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 485-494.	8.2	62
53	The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more?. <i>Hepatology</i> , 2009, 49, n/a-n/a.	3.6	2
54	Hepatitis A virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1997-2005.	1.9	8

#	ARTICLE	IF	CITATIONS
55	HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C. <i>Journal of Hepatology</i> , 2009, 51, 964-966.	1.8	18
56	Pegylated interferon $\hat{1}\pm 2b$ versus pegylated interferon $\hat{1}\pm 2a$ for chronic hepatitis C: The unreached goal of superiority. <i>Journal of Hepatology</i> , 2009, 51, 1097-1099.	1.8	4
57	A 28-Year Study of the Course of Hepatitis $\hat{1}$ Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 136, 1629-1638.	0.6	285
58	Pegylated IFN- $\hat{1}\pm 2a$ and ribavirin in the treatment of hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 925-935.	2.0	19
59	The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. <i>Antiviral Therapy</i> , 2009, 14, 789-796.	0.6	15
60	The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , 2009, 14, 577-84.	0.6	16
61	The pattern of pegylated interferon- $\hat{1}\pm 2b$ and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , 2009, 14, 577-584.	0.6	30
62	Is a 24-week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?. <i>Journal of Viral Hepatitis</i> , 2008, 15, 471-471.	1.0	0
63	Primary prophylaxis of variceal bleeding in cirrhotic patients: A cohort study. <i>Digestive and Liver Disease</i> , 2008, 40, 936-943.	0.4	20
64	Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. <i>European Journal of Internal Medicine</i> , 2008, 19, 370-371.	1.0	24
65	Natural History and Clinical Impact of Cryoglobulins in Chronic Hepatitis C: 10-Year Prospective Study of 343 Patients. <i>Gastroenterology</i> , 2007, 133, 835-842.	0.6	34
66	Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. <i>Antiviral Therapy</i> , 2007, 12, 1033-40.	0.6	2
67	Lack of Rapid Virological Response Predicts Interferon- $\hat{1}\pm 2b$ /Ribavirin Therapy failure in HCV Genotype 2 Patients: A Single-Centre Study. <i>Antiviral Therapy</i> , 2007, 12, 1033-1040.	0.6	8
68	The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. <i>Journal of Hepatology</i> , 2006, 44, 825.	1.8	2
69	Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006, 43, 64-71.	3.6	163
70	High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. <i>Haematologica</i> , 2006, 91, 1367-71.	1.7	18
71	Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. <i>Antiviral Therapy</i> , 2006, 11, 797-802.	0.6	6
72	Impaired Response to Interferon- $\hat{1}\pm 2B$ plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection. <i>Antiviral Therapy</i> , 2006, 11, 797-802.	0.6	15

#	ARTICLE	IF	CITATIONS
73	Onset of inflammatory bowel diseases during combined ??-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1243-1245.	0.8	23
74	Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. <i>Gut</i> , 2005, 54, 402-406.	6.1	61
75	US Features of Liver Surface Nodularity as a Predictor of Severe Fibrosis in Chronic Hepatitis C. <i>Radiology</i> , 2005, 234, 641-641.	3.6	18
76	The Prevalence, Clinical Features and Response to Antiviral Therapy of Patients with Chronic Hepatitis C who are Seropositive for Liverâ€™Kidney Microsome Type 1 Antibodies. <i>Antiviral Therapy</i> , 2005, 10, 715-720.	0.6	8
77	Hepatitis C in haemophilia: lights and shadows. <i>Haemophilia</i> , 2004, 10, 211-215.	1.0	24
78	Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. <i>Transfusion</i> , 2004, 44, 790-794.	0.8	15
79	Serum Levels of Hepatitis C Virus Core Antigen as a Marker of Infection and Response to Therapy. <i>American Journal of Gastroenterology</i> , 2004, 99, 1738-1743.	0.2	21
80	Peginterferon alfa-2b plus ribavirin for naÃƒve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. <i>Journal of Hepatology</i> , 2004, 41, 474-481.	1.8	91
81	Treatment of chronic hepatitis C in Europe. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2003, 10, 168-171.	2.0	9
82	A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. <i>Blood</i> , 2003, 102, 78-82.	0.6	119
83	Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. <i>Gut</i> , 2002, 51, 864-869.	6.1	26
84	Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. <i>Blood</i> , 2002, 99, 1089-1091.	0.6	27
85	Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. <i>Journal of Viral Hepatitis</i> , 2002, 9, 71-74.	1.0	36
86	Performance of the COBAS AMPLICOR HCV MONITOR Test, Version 2.0, an Automated Reverse Transcription-PCR Quantitative System for Hepatitis C Virus Load Determination. <i>Journal of Clinical Microbiology</i> , 2000, 38, 2210-2214.	1.8	40
87	TT Virus Is Present in a High Frequency of Italian Hemophilic Patients Transfused With Plasma-Derived Clotting Factor Concentrates. <i>Blood</i> , 1999, 94, 4333-4336.	0.6	39
88	Serum levels of hepatitis C virus RNA predict non-response to interferon therapy: comparison of two commercial assays. <i>Journal of Viral Hepatitis</i> , 1999, 6, 65-71.	1.0	8
89	Hepatitis C virus RNA profiles in chronically infected individuals: Do they relate to disease activity?. <i>Hepatology</i> , 1999, 29, 585-589.	3.6	76
90	Long-term response to interferon alpha is unrelated toâ€™interferon sensitivity determining regionâ€™ variability in patients with chronic hepatitis C virus-1b infection. <i>Journal of Hepatology</i> , 1999, 30, 1023-1027.	1.8	52

#	ARTICLE	IF	CITATIONS
91	TT Virus Is Present in a High Frequency of Italian Hemophilic Patients Transfused With Plasma-Derived Clotting Factor Concentrates. <i>Blood</i> , 1999, 94, 4333-4336.	0.6	1
92	Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor. <i>Transfusion</i> , 1998, 38, 307-311.	0.8	16
93	High Rates of Hepatitis G Virus Infection in Multitransfused Patients With Hemophilia. <i>Blood</i> , 1997, 90, 4634-4637.	0.6	20
94	Hepatitis C virus genotype 1b and risk of hepatocellular carcinoma. <i>Hepatology</i> , 1997, 26, 1077-1077.	3.6	20
95	High Rates of Hepatitis G Virus Infection in Multitransfused Patients With Hemophilia. <i>Blood</i> , 1997, 90, 4634-4637.	0.6	19
96	A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. <i>Blood</i> , 1997, 89, 3529-33.	0.6	44
97	Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. <i>Journal of Hepatology</i> , 1996, 24, 517-524.	1.8	76
98	Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. <i>Journal of Hepatology</i> , 1996, 24, 33-37.	1.8	39
99	A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. <i>Journal of Hepatology</i> , 1996, 24, 38-47.	1.8	485
100	Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. <i>Transfusion</i> , 1995, 35, 209-212.	0.8	45
101	Alpha interferon treatment of chronic hepatitis C. <i>Biomedicine and Pharmacotherapy</i> , 1995, 49, 111-115.	2.5	10
102	Long-term titrated recombinant interferon- $\alpha$ 2a in chronic hepatitis C: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 1995, 2, 73-76.	1.0	19
103	Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon. <i>Journal of Viral Hepatitis</i> , 1995, 2, 251-256.	1.0	17
104	A multicenter randomized controlled trial of recombinant interferon- $\alpha$ 2b in patients with acute transfusion-associated hepatitis C. <i>Hepatology</i> , 1994, 19, 19-22.	3.6	110
105	Persistence of "wild-type" and "minus" hepatitis B virus infection in chronic healthy HBsAg/anti-HBe positive carriers. <i>Journal of Hepatology</i> , 1994, 20, 148-151.	1.8	24
106	A multicenter randomized controlled trial of recombinant interferon- $\alpha$ 2b in patients with acute transfusion-associated hepatitis C. <i>Hepatology</i> , 1994, 19, 19-22.	3.6	4
107	Accelerated schedule of hepatitis B vaccination in patients with hemophilia. <i>Journal of Medical Virology</i> , 1993, 41, 95-98.	2.5	21
108	Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method. <i>Research in Virology</i> , 1993, 144, 303-306.	0.7	6

#	ARTICLE	IF	CITATIONS
109	Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion.. Gut, 1993, 34, S141-S141.	6.1	11
110	Development of antibody to hepatitis C virus (HCV) in acute and chronic non-A, non-B post-transfusion hepatitis. European Journal of Epidemiology, 1992, 8, 580-584.	2.5	2
111	Hepatitis C antibody in patients with chronic liver disease and hepatocellular carcinoma. Digestive Diseases and Sciences, 1991, 36, 1130-1133.	1.1	33
112	Suboptimal Response to Hepatitis B Vaccine in Drug Users. Archives of Internal Medicine, 1991, 151, 574.	4.3	35
113	High Prevalence of Antibody to Hepatitis C Virus in Multitransfused Hemophiliacs with Normal Transaminase Levels. Annals of Internal Medicine, 1990, 112, 379.	2.0	129
114	Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients. Blood, 1990, 75, 1654-1658.	0.6	14
115	Specificity of the Hepatitis C Virus Antibody ELISA in Patients With Hepatocellular Carcinoma. Journal of the National Cancer Institute, 1990, 82, 1784-1785.	3.0	3
116	Specificity of hepatitis C antibody ELISA in patients with haemophilia. Lancet, The, 1990, 335, 1345.	6.3	67
117	Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients. Blood, 1990, 75, 1654-8.	0.6	4
118	Immunogenicity of a yeast-recombinant hepatitis B vaccine in high-risk children. Journal of Medical Virology, 1989, 27, 48-51.	2.5	3
119	Cryptic hepatitis B virus replication during prednisone therapy in type B chronic active hepatitis. Research in Clinic and Laboratory, 1987, 17, 221-227.	0.3	0
120	Acute Hepatitis B in Children with Papular Acrodermatitis. Pediatric Pathology, 1986, 6, 249-257.	0.5	7
121	Anti-LAV/HTLV-III antibodies in groups of individuals at high risk for infection in Italy. Research in Clinic and Laboratory, 1985, 15, 357-364.	0.3	4
122	HLA-DR Antigens in HBsAg-Positive Chronic Active Liver Disease with and without Associated Delta Infection. Hepatology, 1984, 4, 1107-1110.	3.6	27
123	Liver Disease and Pathology in Hemophilia. Scandinavian Journal of Haematology, 1984, 33, 341-348.	0.0	2
124	Long-term delta superinfection in hepatitis B surface antigen carriers and its relationship to the course of chronic hepatitis. Gastroenterology, 1983, 85, 235-239.	0.6	96
125	Intrafamilial spread of hepatitis B virus infection. Research in Clinic and Laboratory, 1981, 11, 151-8.	0.3	0